NO873562L - Hurtig-absorberende og -virkende kombinasjon av sulindac eller natriumsulindac og en base. - Google Patents
Hurtig-absorberende og -virkende kombinasjon av sulindac eller natriumsulindac og en base. Download PDFInfo
- Publication number
- NO873562L NO873562L NO873562A NO873562A NO873562L NO 873562 L NO873562 L NO 873562L NO 873562 A NO873562 A NO 873562A NO 873562 A NO873562 A NO 873562A NO 873562 L NO873562 L NO 873562L
- Authority
- NO
- Norway
- Prior art keywords
- sulindac
- sodium
- tromethamine
- combination
- treatment
- Prior art date
Links
- YMXUJDLCLXHYBO-WPTDRQDKSA-M sodium;2-[(3z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetate Chemical compound [Na+].CC1=C(CC([O-])=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 YMXUJDLCLXHYBO-WPTDRQDKSA-M 0.000 title claims description 41
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 title claims description 32
- 229960000894 sulindac Drugs 0.000 title claims description 32
- 229960000281 trometamol Drugs 0.000 claims description 33
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 31
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 15
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims description 8
- 229940049654 glyceryl behenate Drugs 0.000 claims description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 8
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 8
- 229920002261 Corn starch Polymers 0.000 claims description 6
- 238000010521 absorption reaction Methods 0.000 claims description 6
- 239000008120 corn starch Substances 0.000 claims description 6
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 claims description 5
- 229960000878 docusate sodium Drugs 0.000 claims description 5
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 16
- 239000003826 tablet Substances 0.000 description 13
- 206010061218 Inflammation Diseases 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- LFWHFZJPXXOYNR-RQZCQDPDSA-N 2-[(3e)-6-fluoro-2-methyl-3-[(4-methylsulfanylphenyl)methylidene]inden-1-yl]acetic acid Chemical compound C1=CC(SC)=CC=C1\C=C/1C2=CC=C(F)C=C2C(CC(O)=O)=C\1C LFWHFZJPXXOYNR-RQZCQDPDSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical class CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000004575 Infectious Arthritis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Chemical class C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940018602 docusate Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical class C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 229940100692 oral suspension Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 201000001223 septic arthritis Diseases 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229960001407 sodium bicarbonate Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Absorbent Articles And Supports Therefor (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/900,201 US4704405A (en) | 1986-08-25 | 1986-08-25 | Rapid acting combination of sodium sulindac and a base |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO873562D0 NO873562D0 (no) | 1987-08-24 |
| NO873562L true NO873562L (no) | 1988-02-26 |
Family
ID=25412127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO873562A NO873562L (no) | 1986-08-25 | 1987-08-24 | Hurtig-absorberende og -virkende kombinasjon av sulindac eller natriumsulindac og en base. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US4704405A (ko) |
| EP (1) | EP0259990A1 (ko) |
| JP (1) | JPS6388122A (ko) |
| KR (1) | KR880002515A (ko) |
| CN (1) | CN87105828A (ko) |
| AU (2) | AU4028772A (ko) |
| DK (1) | DK440587A (ko) |
| FI (1) | FI873550A (ko) |
| HU (1) | HUT44925A (ko) |
| IL (1) | IL83579A0 (ko) |
| NO (1) | NO873562L (ko) |
| PT (1) | PT85566B (ko) |
| ZA (1) | ZA876253B (ko) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989005798A1 (en) * | 1987-12-18 | 1989-06-29 | Ciba-Geigy Ag | TROMETHAMINE SALT OF 1-METHYL-beta-OXO-alpha-(PHENYLCARBAMOYL)-2-PYRROLEPROPIONITRILE |
| GR880100839A (el) * | 1988-12-15 | 1994-03-31 | Ciba Geigy | Αλας τρομε?αμίνης του 1-με?ύλ-Β-ΟΞΟ-Α-(φαινυλοκαρβομουλό)-2-πυρρολοπροπιονιτριλίου. |
| KR920002148A (ko) * | 1990-07-03 | 1992-02-28 | 안드레아 엘. 콜비 | 비스테로이드계 소염제에 의해 유발된 위장 증상을 완화시키기 위한 약제 조성물 및 이를 완화시키는 방법 |
| US5183829A (en) * | 1991-09-27 | 1993-02-02 | Applied Analytical Industries, Inc. | Oral liquid compositions of non-steroidal anti-inflammatory drugs |
| US5288507A (en) * | 1992-07-29 | 1994-02-22 | Merck & Co., Inc. | Ibuprofen antacid combinations |
| US6365180B1 (en) | 1998-01-20 | 2002-04-02 | Glenn A. Meyer | Oral liquid compositions |
| ATE429210T1 (de) | 1998-01-20 | 2009-05-15 | Applied Analytical Ind Inc | Orale flüssige zusammensetzungen |
| KR100385366B1 (ko) * | 2001-03-05 | 2003-05-27 | 부광약품 주식회사 | 생체이용율을 개선한 실리마린 제제 조성물 |
| US20030152622A1 (en) * | 2001-10-25 | 2003-08-14 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral diuretic |
| US20030091630A1 (en) * | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
| KR20030029067A (ko) * | 2003-02-10 | 2003-04-11 | 정진욱 | 토탄과 하수종말처리장 슬라지 폐기물을 배합한 가래 탄과그 제조방법. |
| JP2007527394A (ja) * | 2003-07-01 | 2007-09-27 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 拡散層調節固体 |
| ITMI20032523A1 (it) | 2003-12-19 | 2005-06-20 | Acraf | Forma di dosaggio per uso orale comprendente un farmaco |
| WO2005077394A1 (en) * | 2004-02-11 | 2005-08-25 | Ramot At Tel-Aviv University Ltd | Compositions for treatment of cancer and inflammation with curcumin and at least one nsaid |
| GB2411355B (en) | 2004-02-27 | 2006-02-22 | Niche Generics Ltd | Pharmaceutical composition |
| US8216610B2 (en) * | 2004-05-28 | 2012-07-10 | Imaginot Pty Ltd. | Oral paracetamol formulations |
| JP2008500288A (ja) | 2004-05-28 | 2008-01-10 | イメイジノット ピーティーワイ エルティーディー | 経口治療用化合物の供給系 |
| KR100576332B1 (ko) * | 2004-07-16 | 2006-05-03 | 강승우 | 신규한 글라이세리드 유도체 및 이를 포함하는 통증완화용조성물 |
| KR100621119B1 (ko) * | 2005-07-28 | 2006-09-07 | (주)삼창뉴텍 | 고체 화석연료의 고화 방법 |
| AU2006317530B2 (en) | 2005-11-28 | 2011-09-01 | Imaginot Pty Ltd | Oral therapeutic compound delivery system |
| US9289409B2 (en) * | 2008-04-18 | 2016-03-22 | Warsaw Orthopedic, Inc. | Sulindac formulations in a biodegradable material |
| US20100098746A1 (en) * | 2008-10-20 | 2010-04-22 | Warsaw Orthopedic, Inc. | Compositions and methods for treating periodontal disease comprising clonidine, sulindac and/or fluocinolone |
| US20150250750A1 (en) | 2012-10-16 | 2015-09-10 | Wockhardt Limited | Pharmaceutical compostions of diclofenac or salts thereof |
| WO2014060856A1 (en) | 2012-10-16 | 2014-04-24 | Wockhardt Limited | Pharmaceutical compositions of diclofenac or salts thereof |
| WO2014060857A1 (en) | 2012-10-19 | 2014-04-24 | Wockhardt Limited | Pharmaceutical compositions of diclofenac or salts thereof |
| CN106580938A (zh) * | 2016-12-26 | 2017-04-26 | 云南中医学院 | 一种氨丁三醇有机酸盐及其制备方法和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE134672C (ko) * | ||||
| US3654349A (en) * | 1970-05-01 | 1972-04-04 | Merck & Co Inc | Substituted indenyl acetic acids |
| HU185926B (en) * | 1979-09-27 | 1985-04-28 | Agostne Kahan | Process for preparing water soluble derivatives of non-steroid antiinflammatory compositions and pharmaceutical compositins containing such derivatives |
| US4402979A (en) * | 1980-03-21 | 1983-09-06 | Merck & Co., Inc. & Laboratories | Ophthalmic formulations of 5-fluoro-2-methyl-1-(p-methylthiobenzylidene)-3-indenylacetic acid |
| US4307114A (en) * | 1980-06-19 | 1981-12-22 | Ayerst, Mckenna & Harrison, Inc. | Aldose reductase inhibition by (Z)-5-fluoro-2-methyl-1-[[4-(methylsulfinyl)phenyl]methylene]-1H-indene-3-acetic acid |
-
1972
- 1972-03-22 AU AU40287/72A patent/AU4028772A/en not_active Expired
-
1986
- 1986-08-25 US US06/900,201 patent/US4704405A/en not_active Expired - Fee Related
-
1987
- 1987-08-17 FI FI873550A patent/FI873550A/fi not_active Application Discontinuation
- 1987-08-18 AU AU77156/87A patent/AU7715687A/en not_active Abandoned
- 1987-08-18 IL IL83579A patent/IL83579A0/xx unknown
- 1987-08-18 EP EP87307295A patent/EP0259990A1/en not_active Withdrawn
- 1987-08-20 PT PT85566A patent/PT85566B/pt unknown
- 1987-08-22 CN CN198787105828A patent/CN87105828A/zh active Pending
- 1987-08-24 NO NO873562A patent/NO873562L/no unknown
- 1987-08-24 ZA ZA876253A patent/ZA876253B/xx unknown
- 1987-08-24 HU HU873737A patent/HUT44925A/hu unknown
- 1987-08-24 DK DK440587A patent/DK440587A/da not_active Application Discontinuation
- 1987-08-25 JP JP62209419A patent/JPS6388122A/ja active Pending
- 1987-08-25 KR KR870009289A patent/KR880002515A/ko not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US4704405A (en) | 1987-11-03 |
| DK440587D0 (da) | 1987-08-24 |
| FI873550A0 (fi) | 1987-08-17 |
| HUT44925A (en) | 1988-05-30 |
| DK440587A (da) | 1988-02-26 |
| ZA876253B (en) | 1988-04-27 |
| IL83579A0 (en) | 1988-01-31 |
| JPS6388122A (ja) | 1988-04-19 |
| FI873550A (fi) | 1988-02-26 |
| EP0259990A1 (en) | 1988-03-16 |
| PT85566B (en) | 1989-11-09 |
| AU7715687A (en) | 1988-02-25 |
| PT85566A (en) | 1987-09-01 |
| CN87105828A (zh) | 1988-04-27 |
| NO873562D0 (no) | 1987-08-24 |
| KR880002515A (ko) | 1988-05-09 |
| AU4028772A (en) | 1973-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO873562L (no) | Hurtig-absorberende og -virkende kombinasjon av sulindac eller natriumsulindac og en base. | |
| JP5874154B2 (ja) | カプサイシノイドの投与 | |
| ES2582376T3 (es) | Método para la mejora de la señalización de islotes en diabetes mellitus y para su prevención | |
| AU764742B2 (en) | Dispersible compositions containing L-DOPA ethyl ester | |
| EA008409B1 (ru) | ФАРМАЦЕВТИЧЕСКИЙ СОСТАВ ДЛЯ ЭФФЕКТИВНОГО ВВЕДЕНИЯ АПОМОРФИНА, 6aR-(-)-N-ПРОПИЛ-НОРАПОМОРФИНА, ИХ ПРОИЗВОДНЫХ И ИХ ПРОЛЕКАРСТВ | |
| NO329143B1 (no) | Bruseformuleringer og fremgangsmate for fremstilling derav. | |
| KR101272470B1 (ko) | 레보드로프로피진을 포함하는 속효성과 지속성을 동시에 갖는 약제학적 조성물 | |
| BG64348B1 (bg) | Лекарствена форма за гълтане, съдържаща парацетамол | |
| US7939518B2 (en) | Method of treating post-surgical acute pain | |
| JPS5841821A (ja) | 最少化された胃の損傷を示す抗炎症組成物 | |
| AU773352B2 (en) | Preventive or therapeutic agents for inflammatory diseases of intestine | |
| Hey et al. | A gastroscopic and pharmacological study of the disintegration time and absorption of pivampicillin capsules and tablets. | |
| WO2012018742A2 (en) | Dextromethorphan antitussive compositions | |
| CN100500151C (zh) | 一种水溶性药物舌下给药制剂 | |
| WO2007099559A2 (en) | Method of preparation for novel composition of 2-{(2,6 dichlorophenyl) amino] benzeneacetic acid carboxymethyl ester or 2-[2-[2-(2,6-dichlorophenyl) amino] phenylacetoxyacetic acid and method of its use | |
| CN100427089C (zh) | 吲唑衍生物用于制备治疗神经病性疼痛药物的用途 | |
| US20070213324A1 (en) | Stable pharmaceutical composition of carisoprodol and meloxicam | |
| KR100809778B1 (ko) | 새로운 2-(알파-엔-펜타노일)벤조에이트들과, 그들의제조와 사용 | |
| RU2182016C2 (ru) | Спазмолитическая композиция, способ получения спазмолитической композиции | |
| BRPI0617184A2 (pt) | formulação de pralnacasan com liberação retardada | |
| KR100631873B1 (ko) | 생체이용율이 증진된 알렌드론산 제제 | |
| EP0868915A1 (en) | An anti-spasmodic and antiinflammatory composition containing a NSAID, pentifenone and fenpiverinium | |
| RU2203671C1 (ru) | Противовирусный лекарственный препарат для перорального применения | |
| WO2023284426A1 (zh) | 一种抗痛风的芹槐提取物与非布司他药物组合物及其用途 | |
| Mutch | Drugs in the treatment of rheumatic disorders |